McKesson (MCK) on Thursday announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new reporting structure enhances strategic alignment and transparency, supporting optimizing portfolio management to drive sustainable long-term value creation for shareholders, the company said in a statement. Britt Vitalone, CFO, said: “This updated reporting structure reflects a strategic evolution of our business – accelerating growth in the high-margin areas of oncology, multispecialty, and biopharma services. It enhances transparency and reinforces our disciplined approach to capital allocation and shareholder value creation.” The new reportable segments are: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions, and Other.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson’s Strategic Restructuring and Growth Potential Earns ‘Buy’ Rating from Analyst
- McKesson Announces New Reporting Segments Restructure
- McKesson price target raised to $772 from $766 at Wells Fargo
- McKesson’s Strong Long-Term Growth Potential Justifies Buy Rating Despite Limited Immediate Upside
- McKesson’s Earnings Call Highlights Strong Growth and Strategic Moves